www.smartbrief.com/news/aaaa/industryBW-detail.jsp?id=3 -
[Cached Version]
Published on: 10/31/2007
Last Visited: 10/31/2007
PASADENA, Calif.-- (BUSINESS WIRE) -- Arrowhead Research Corporation (NASDAQ:ARWR), announced today that Larry G. Stambaugh has been appointed as President and Chief Executive Officer of two of its majority-owned subsidiaries, Calando Pharmaceuticals, Inc. and Insert Therapeutics, Inc., and that a merger between the two companies is being pursued.Both companies are developing anti-cancer drugs.Insert is already in clinical studies with its first drug candidate and Calando is preparing to file an investigational new drug (IND) application for its first RNAi-based drug candidate.
"Larry has an impressive track record of raising over $350 million of capital, running 17 clinical trials, including four Phase 3 trials, and securing partnerships with major pharmaceutical companies as the former CEO of Maxim Pharmaceuticals, Inc.," said R. Bruce Stewart, Chairman and CEO of Arrowhead.
...
"I am pleased to have the opportunity to join the Calando and Insert teams and to advance the development of their exciting technologies into new effective treatments for cancer and other diseases, and bring them to patients in large unmet need markets," said Stambaugh."The proposed combination maximizes strong synergies between the two companies, joins a shared strategic vision, and provides for the efficient use of resources under the Arrowhead umbrella."
Mr. Stambaugh is the former Chairman, CEO and co-founder for Maxim Pharmaceuticals, Inc.At Maxim, he established a public, global biopharmaceutical company with a pipeline of product candidates for life-threatening cancers and liver diseases.During his time with Maxim he took the company public in the U.S. and Europe, conducted 17 clinical trials, including four phase 3 studies, in over 20 countries, established several corporate partnerships with large pharmaceutical companies and acquired a promising biotechnology company.In 2006, he merged Maxim with an East Coast biotech company.Previously, he was the Chairman, President and CEO for ABC Laboratories, a world-leading environmental research laboratory serving Fortune 100 pharmaceutical and chemical companies.Mr. Stambaugh has worked as a top executive in banking, manufacturing, and retail and began his career at KPMG.He has a B.B.A. from Washburn University and is a C.P.A.
He has recently been a principal at Apercu Consulting, where he serves as an advisor to private and public boards and management, and has participated in launching several new companies.Larry has more than 75 years of combined board service and speaks on the best practices and current issues in corporate governance.In 2002 and again in 2006 and 2007, he was awarded the "Director of the Year" recognition for his work in corporate governance leadership and education from the Corporate Directors Forum in San Diego, where he launched one of the top annual conferences for corporate governance in the United States today.
259 online sources [ view sources ]
